Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial

Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial

Introduction: The study (ClinicalTrials.gov, NCT04346914) is an open label, single-arm, phase 1b clinical trial investigating the safety, tolerability, and efficacy of the recombinant human anti–programmed death-ligand 1 monoclonal antibody socazolimab in combination with carboplatin and etoposide i...

Full description

Bibliographic Details
Main Authors: Shun Lu, PhD, MD, Zhiwei Chen, MD, Jiuwei Cui, MD, Renhua Guo, MD, Ziming Li, MD, Benjamin Xiaoyi Li, PhD, Xiangrong Dai, PhD
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:JTO Clinical and Research Reports
Subjects:
Socazolimab
Extensive-stage small cell lung cancer (ES-SCLC)
Carboplatin
Etoposide
PD-L1
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323000176

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323000176

Similar Items